Brought to you by 
Watson gets US rights to Columbia's progesterone assets; agreement later ends
21 Aug 2018
Executive Summary
Just days after gaining rights to the Population Council's contraceptive vaginal ring, Watson Pharmaceuticals Inc. has signed another deal in women's health, gaining exclusive US rights to Columbia Laboratories Inc.'s (drug delivery technologies) progesterone assets. Included in the $47mm up-front payment is the purchase of 11.2mm common shares at the current market price.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson gets US rights to Columbia's progesterone assets; agreement later ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice